A long QT syndrome genetic test looks for inherited variants that delay the heart’s electrical recovery after each beat. The three most important genes are KCNQ1, KCNH2, and SCN5A, which cause the common subtypes known as LQT1, LQT2, and LQT3. A pathogenic result can confirm congenital long QT syndrome, identify relatives who need evaluation, and help clinicians tailor trigger avoidance and treatment. Genetic testing is not a stand-alone screening test for every fainting episode or borderline electrocardiogram. Diagnosis combines the corrected QT interval, symptoms, family history, medication and electrolyte review, exercise or standing responses, and molecular findings. This distinction matters because QT prolongation can also be acquired from medicines, low potassium or magnesium, severe illness, and other heart conditions. A normal ECG does not fully exclude inherited disease, while a prolonged QTc does not automatically prove a genetic syndrome.
- KCNQ1, KCNH2, and SCN5A account for most genetically explained cases of classic congenital long QT syndrome.
- A positive result identifies a disease-causing variant but does not precisely predict whether or when an arrhythmia will occur.
- A negative panel cannot rule out long QT syndrome when the ECG, symptoms, or family history remain convincing.
- No fasting is needed; testing usually uses blood or saliva and takes roughly two to eight weeks.
- A variant of uncertain significance is not proof of long QT syndrome and should not guide predictive family testing by itself.
- Fainting during exercise, sudden startling, swimming, or sleep—and any resuscitated cardiac arrest—requires prompt specialist assessment.
Table of Contents
- The Electrical Problem and the Test’s Purpose
- Who Benefits From Genetic Testing
- KCNQ1, KCNH2, and SCN5A Differences
- The Testing Process
- How to Read the Genetic Report
- How ECG and Genetic Results Fit Together
- Treatment, Medicines, Exercise, and Daily Life
- Relatives and Future Planning
The Electrical Problem and the Test’s Purpose
The QT interval is the portion of an electrocardiogram, or ECG, that represents activation and recovery of the heart’s lower chambers. Because QT duration changes with heart rate, clinicians use a corrected value called QTc. Congenital long QT syndrome, or LQTS, occurs when ion channels and related proteins do not move electrical particles across heart-cell membranes normally. Recovery takes longer, creating a vulnerable period when a dangerous rhythm such as torsades de pointes can start.
The genetic test examines genes that build or regulate these channels. Its main purposes are to:
- Confirm a suspected inherited diagnosis.
- Distinguish congenital disease from isolated acquired QT prolongation.
- Identify a subtype that may influence triggers and treatment.
- Find relatives who carry the familial variant before symptoms occur.
- Clarify risk after an unexplained cardiac arrest or sudden death in a family.
The test does not directly measure QTc. It cannot show whether potassium is low, whether a medicine is prolonging repolarization, or whether the person has an active arrhythmia. Those questions require ECGs, laboratory tests, medication review, ambulatory monitoring, exercise testing, and clinical assessment.
QTc thresholds are not absolute. Measurements vary with the correction formula, heart rate, age, sex, lead selection, and manual technique. A single automated ECG reading can overestimate or underestimate the interval. Persistent QTc values around or above 480 milliseconds strongly raise concern in the right setting, but some genetically affected people have QTc values within the usual range. Conversely, fever, electrolyte loss, starvation, bradycardia, and medications can prolong QTc in someone without congenital LQTS.
A genetic diagnostic test therefore adds molecular evidence to a clinical diagnosis rather than replacing it.
Who Benefits From Genetic Testing
Testing is most useful when the pretest probability is meaningful. It is commonly considered for people with a clear clinical diagnosis, a repeatedly prolonged QTc without an adequate acquired explanation, characteristic symptoms, or a close relative with a confirmed pathogenic variant.
Clinical situations that may justify testing include:
- Unexplained fainting during exercise, swimming, sudden emotion, an alarm sound, or sleep.
- Documented torsades de pointes or polymorphic ventricular tachycardia.
- A resuscitated cardiac arrest without structural heart disease or another cause.
- Repeated prolonged QTc values after medication and electrolyte causes are addressed.
- Congenital deafness with marked QT prolongation, suggesting Jervell and Lange-Nielsen syndrome.
- A first-degree relative with congenital LQTS or an established familial variant.
- Sudden unexplained death at a young age, especially during exertion, startle, or sleep.
Testing may also be appropriate when the clinical picture is intermediate but the result would change management. A specialist may calculate a clinical probability score and review serial ECGs, exercise recovery, standing responses, and family records before ordering a panel.
Broad testing of people with one borderline QTc and no supporting history can produce more uncertain findings than useful answers. Rare benign variation is common in ion-channel genes. When the initial probability is low, a variant of uncertain significance can be mistaken for a diagnosis and lead to unnecessary fear, medication, or activity restriction.
The best person to test first is usually the most clearly affected family member. If a pathogenic variant is found, healthy relatives can have inexpensive targeted testing for that exact change. Starting with an unaffected relative when no familial variant is known may leave the family with an uninformative negative result.
Genetic testing should also be distinguished from the evaluation of medication-related QT prolongation. Someone who develops a long QT only while taking a high-risk drug or during severe hypokalemia may have an acquired problem, an inherited susceptibility, or both. A specialist decides whether the severity, persistence, and family history justify a congenital LQTS panel.
KCNQ1, KCNH2, and SCN5A Differences
KCNQ1, KCNH2, and SCN5A explain the large majority of positive results in people with a well-established molecular diagnosis. Each gene affects a different current in the cardiac action potential, and the resulting patterns can differ.
| Gene | Subtype | Typical mechanism | Commonly reported triggers |
|---|---|---|---|
| KCNQ1 | LQT1 | Reduced slow delayed rectifier potassium current | Exercise, especially swimming; intense emotion |
| KCNH2 | LQT2 | Reduced rapid delayed rectifier potassium current | Sudden auditory startle, emotion, postpartum period |
| SCN5A | LQT3 | Persistent inward sodium current during repolarization | Rest, sleep, slow heart rates |
These associations are tendencies, not rules. A person with KCNQ1-related disease can have an event at rest, and a person with SCN5A-related disease can have exertional symptoms. Treatment must reflect the whole clinical picture.
KCNQ1 variants usually cause autosomal dominant Romano-Ward syndrome. When a child inherits pathogenic variants in both KCNQ1 copies, severe LQTS with congenital hearing loss may occur. KCNQ1-related events often arise during adrenergic stress, and beta blockers are especially effective when taken consistently.
KCNH2, historically called HERG, encodes a potassium channel that is also sensitive to many medications. KCNH2-related disease may be provoked by sudden noises, emotional stress, and the postpartum period. The exact location and type of variant can influence risk, although variant-level predictions are not perfect.
SCN5A encodes the main cardiac sodium channel. Gain-of-function variants can cause LQT3, while other SCN5A variants can produce Brugada syndrome, conduction disease, sick sinus syndrome, atrial arrhythmias, or overlapping phenotypes. The same gene name therefore does not establish the same diagnosis; the specific variant mechanism and phenotype matter. Related evaluation may include a Brugada syndrome genetic test when the ECG or family history suggests an overlap.
Other genes can cause syndromic or rare forms, including CALM1, CALM2, CALM3, TRDN, CACNA1C, and KCNE1. Modern panels may include many genes, but laboratories should prioritize those with strong disease evidence. Reporting weakly supported genes can increase false attribution.
Most classic LQTS follows autosomal dominant inheritance. Each child of an affected person has a 50% chance of inheriting the variant. Penetrance is incomplete, so a carrier can have a normal or borderline QTc and still transmit the variant.
The Testing Process
Testing usually begins with a cardiovascular genetics or inherited arrhythmia consultation. The clinician reviews original ECG tracings rather than relying only on a report. Important records include exercise tests, ambulatory monitors, medication lists, electrolyte values, emergency notes, and autopsy or death-certificate information for affected relatives.
A blood sample is common, though saliva or a cheek swab may be accepted. No fasting or medication pause is needed for DNA collection. People should not stop beta blockers or other prescribed medicines simply because genetic testing is planned.
The laboratory typically performs next-generation sequencing across a panel of LQTS and overlapping arrhythmia genes. It may add deletion and duplication analysis to detect missing or extra exons. Selected variants are often confirmed by a second method before reporting.
Turnaround is commonly two to eight weeks. The report should identify:
- The gene and exact DNA and protein change.
- The laboratory classification.
- The inheritance pattern.
- The evidence used for classification.
- The test’s coverage and technical limitations.
- Whether family testing is available.
Testing after sudden unexplained death may use stored blood, frozen tissue, or another suitable specimen in a molecular autopsy. Formalin-fixed tissue can be more difficult because DNA may be fragmented. A negative postmortem panel does not exclude an inherited arrhythmia, so surviving relatives often still need ECG-based evaluation.
Insurance authorization, consent, and privacy issues vary. Genetic counseling should cover the possibility of uncertain findings, unexpected familial relationships, and implications for relatives. It should also explain that legal protections against genetic discrimination differ by country and may not apply to every form of insurance.
How to Read the Genetic Report
A report is clinically actionable only when the variant classification and the person’s phenotype support the same conclusion.
Pathogenic or likely pathogenic
A pathogenic or likely pathogenic variant in KCNQ1, KCNH2, SCN5A, or another validated gene can confirm the molecular diagnosis when it fits the clinical findings. “Likely pathogenic” generally means the laboratory believes the probability of disease causation is very high, though not mathematically certain.
A positive result can guide cascade testing, but it does not provide a personal countdown to an event. Risk varies with QTc, sex, age, prior fainting, prior cardiac arrest, variant location and type, treatment adherence, and exposure to triggers.
Negative
A negative result means no reportable pathogenic variant was found with the methods used. It does not mean the person has no arrhythmia risk. Possible reasons include an undetectable variant, a gene not tested, a gene not yet discovered, mosaicism, or a clinically diagnosed form without an identifiable molecular cause.
Clinical treatment may continue after a negative panel when the phenotype is convincing. Relatives may also need ECG screening if the family history remains concerning.
Variant of uncertain significance
A VUS has insufficient evidence for a benign or pathogenic classification. It should not be treated as a positive result. Healthy relatives should not be labeled affected solely because they share it, and a VUS should not be the only reason for an implantable defibrillator, lifelong drug therapy, or major exercise restriction.
Family segregation studies can sometimes help, especially when several clearly affected relatives are available. Functional studies and new population data may later reclassify the variant. The patient should keep contact details current with the clinic and ask how amended reports are issued. A fuller explanation is available in the VUS result guide.
Benign or likely benign
These variants are not considered a cause of LQTS and usually do not appear prominently on the final report. They should not influence care.
How ECG and Genetic Results Fit Together
Four common result combinations illustrate why neither test works alone.
| Clinical findings | Genetic result | Interpretation |
|---|---|---|
| Clearly prolonged QTc with characteristic symptoms | Pathogenic variant | Strong clinical and molecular confirmation; use genotype-informed care. |
| Normal or borderline QTc | Known familial pathogenic variant | Genotype-positive with reduced penetrance; surveillance and prevention still matter. |
| Clearly prolonged QTc after acquired causes are excluded | Negative panel | Clinical LQTS may remain; manage phenotype and review test limitations. |
| One borderline automated QTc | VUS | Diagnosis is not established; repeat expert ECG review and avoid overinterpretation. |
QTc should be measured manually when the diagnosis is uncertain, especially if the T-wave shape is complex. Bazett correction is widely used but can overcorrect at fast rates and undercorrect at slow rates. Clinicians may compare formulas and serial tracings.
Exercise testing can reveal abnormal QT adaptation during recovery. Standing abruptly can also expose repolarization behavior. Epinephrine testing is used selectively and is not required for every patient. Holter monitors help assess rhythm and heart-rate patterns but do not replace a standard 12-lead ECG.
Acquired causes must be addressed. Common contributors include low potassium, low magnesium, marked bradycardia, starvation or eating disorders, vomiting or diarrhea, and QT-prolonging medicines. The inherited and acquired categories can overlap: a carrier with modest baseline QT prolongation may have a dangerous increase after medication or electrolyte loss.
Treatment, Medicines, Exercise, and Daily Life
Treatment aims to prevent syncope, torsades de pointes, cardiac arrest, and sudden death. The plan depends on symptoms, QTc, genotype, age, and previous events.
Nonselective beta blockers such as nadolol or propranolol are commonly preferred because evidence suggests they protect better than some selective agents in congenital LQTS. Doses are adjusted to body size, heart rate, blood pressure, side effects, and exercise response. Missing doses can sharply reduce protection, particularly in LQT1 and LQT2.
Mexiletine may shorten QTc and reduce events in selected people with SCN5A-related LQT3, especially when the variant and ECG response support persistent sodium current as the mechanism. It is not a universal treatment for every SCN5A finding.
An implantable cardioverter-defibrillator may be appropriate after cardiac arrest or for selected high-risk patients with events despite effective therapy. Devices can save lives but also carry risks, including inappropriate shocks, infection, lead problems, and psychological burden. Left cardiac sympathetic denervation is another option for selected people who remain high risk, cannot tolerate adequate medication, or experience recurrent shocks.
Daily precautions usually include:
- Checking medicines against a trusted QT-risk resource before starting them.
- Correcting vomiting, diarrhea, or other causes of electrolyte loss promptly.
- Maintaining prescribed beta-blocker dosing during travel and routine changes.
- Creating an emergency plan for schools, coaches, and caregivers.
- Discussing swimming supervision and exercise with an inherited-arrhythmia specialist.
- Ensuring household members know cardiopulmonary resuscitation when feasible.
Modern exercise advice is individualized rather than automatically prohibiting all sports. A treated, asymptomatic person with a lower-risk profile may participate under shared specialist guidance, while someone with recent exertional syncope or uncontrolled QT prolongation needs stricter limits. Automated wearable QT estimates are not reliable enough to replace medical ECG measurement.
Relatives and Future Planning
When a pathogenic variant is found, first-degree relatives should be offered targeted testing and clinical evaluation. Children can be tested because preventive treatment and trigger avoidance may be needed during childhood. A relative who tests negative for the known familial variant is generally released from syndrome-specific genetic surveillance, unless separate clinical findings require care.
A positive relative needs at least a baseline ECG and specialist review even without symptoms. Reduced penetrance means a normal QTc does not erase inherited risk. The clinician may recommend exercise testing, ambulatory monitoring, or repeated ECGs based on age and gene.
If no variant is identified in the proband, relatives cannot be cleared by a targeted DNA test. Clinical screening remains important. Families with sudden unexplained deaths may benefit from coordinated evaluation through an inherited arrhythmia clinic rather than isolated ECGs ordered without pedigree review.
Pregnancy is often tolerated with careful care, but risk changes by subtype and time period. KCNH2-related LQT2 carries particular concern in the postpartum months. Medication planning should occur before conception because abrupt beta-blocker withdrawal can be dangerous, while fetal growth and neonatal effects may require monitoring. Labor, anesthesia, anti-nausea drugs, antibiotics, and electrolyte management should be planned with obstetric and cardiac teams.
A person with a pathogenic autosomal dominant variant has a 50% chance of passing it to each child. Reproductive options include natural conception, prenatal diagnosis, and in vitro fertilization with preimplantation genetic testing for the known familial variant. The result can predict inheritance, not exact severity.
The most effective use of testing is a family-based system: identify the causal variant in an affected person, test relatives accurately, and connect carriers to preventive care before the first dangerous event.
Families should keep a portable record that includes the gene, exact variant, current medicines, allergies, most recent ECG, treating specialist, and emergency instructions. A gene name alone is not enough because different variants in the same gene can have different effects. Sharing the original laboratory report prevents relatives from being tested for the wrong change and helps new clinicians verify the classification.
Periodic review remains important even after the family has been evaluated. Children grow, medication doses change, new drugs become available, and variant classifications can be updated. A teenager who was stable on a childhood dose may become under-treated after a growth spurt. An adult who develops kidney disease, starts a diuretic, or has recurrent vomiting may face new electrolyte-related risk. Follow-up should therefore address current physiology as well as inherited status.
Psychological responses also deserve attention. Some carriers feel well and struggle with the idea of lifelong prevention; others become afraid of normal exercise or every palpitation. Clear, written guidance can reduce both under-treatment and unnecessary restriction. Counseling should distinguish warning symptoms from common benign sensations, explain when emergency care is appropriate, and provide realistic expectations about school, work, travel, and family life.
When relatives live in different regions, the original clinic can provide a family letter describing the diagnosis and recommended targeted test without disclosing more personal information than necessary. Each relative still needs their own clinician and consent process. Testing should never be inferred from another person’s result: a 50% inheritance probability means some relatives will carry the variant and others will not. Relatives should also avoid copying medication choices from one another, because age, asthma, blood pressure, rhythm history, pregnancy, and side effects can make the safest plan different even within the same family.
References
- Long QT Syndrome Overview 2024 (Review)
- 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death 2022 (Guideline)
- EHRA/HRS/APHRS/LAHRS Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases 2022 (Position Statement)
- The Clinical Diagnosis and Management of Long QT Syndrome: Insights from the 2022 ESC Guidelines 2023 (Review)
- A comprehensive review of long QT syndrome: Advances in diagnosis and treatment 2024 (Review)
- Management of Long QT Syndrome: A Systematic Review 2024 (Systematic Review)
Disclaimer
This article is for general education and does not diagnose long QT syndrome or replace ECG interpretation by an inherited-arrhythmia specialist. Do not stop heart medicines or start, stop, or substitute QT-prolonging drugs without clinical advice. Fainting with exertion or startle, seizure-like collapse, palpitations with near-fainting, or cardiac arrest requires urgent medical evaluation.
